GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Day One Biopharmaceuticals Inc (NAS:DAWN) » Definitions » Operating Margin %

Day One Biopharmaceuticals (Day One Biopharmaceuticals) Operating Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Day One Biopharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Day One Biopharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $-66.77 Mil. Day One Biopharmaceuticals's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Day One Biopharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Day One Biopharmaceuticals's Operating Margin % or its related term are showing as below:


DAWN's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -169.17
* Ranked among companies with meaningful Operating Margin % only.

Day One Biopharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Day One Biopharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $-66.77 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-226.98 Mil.


Day One Biopharmaceuticals Operating Margin % Historical Data

The historical data trend for Day One Biopharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Day One Biopharmaceuticals Operating Margin % Chart

Day One Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
- - - - -

Day One Biopharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Day One Biopharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Day One Biopharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Day One Biopharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Day One Biopharmaceuticals's Operating Margin % falls into.



Day One Biopharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Day One Biopharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-206.064 / 0
= %

Day One Biopharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-66.767 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Day One Biopharmaceuticals  (NAS:DAWN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Day One Biopharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Day One Biopharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Day One Biopharmaceuticals (Day One Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2000 Sierra Point Parkway, Suite 501, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Executives
York Charles N Ii officer: COO, CFO and Secretary 901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746
Samuel C. Blackman officer: Chief Medical Officer 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Jeremy Bender director, officer: Chief Executive Officer 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Ai Day 1 Llc 10 percent owner 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Julie Papanek Grant director 2765 SAND HILL ROAD, MENLO PARK CA 94025
Canaan Xi L.p. 10 percent owner 2765 SAND HILL RD, MENLO PARK CA 94025
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Michael Gladstone director 395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Takeda Pharmaceuticals U.s.a., Inc. 10 percent owner ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John A. Josey director C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235

Day One Biopharmaceuticals (Day One Biopharmaceuticals) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold Day One Biopharmaceuticals Inc Shares

By GuruFocus Research GuruFocus Editor 05-19-2023

This Insider Just Sold Shares of Day One Biopharmaceuticals Inc

By GuruFocus Research GuruFocus Editor 05-18-2023

Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Value_Insider Value_Insider 12-20-2022

Insider Alert: An Insider Just Sold Day One Biopharmaceuticals Inc Shares

By GuruFocus Research GuruFocus Editor 01-25-2023

Day One Announces Pricing of Public Offering of Common Stock

By sperokesalga sperokesalga 06-07-2023